Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023933 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
A Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00023933: Completed Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer, sponsored by National Cancer Institute (NCI).
NCT00023933 is a Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants, below the 910-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023933, a Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective treatment for colorectal cancer
Conditions Studied
Interventions
- DRUG iodine I 131 monoclonal antibody CC49-deltaCH2
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2001-10 |
| Phase | Phase 1 |
What the finished NCT00023933 record still lists
NCT00023933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 910-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (98% lower).
The record links to 6 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 1 intervention - of which iodine I 131 monoclonal antibody CC49-deltaCH2 is the first listed.
NCT00023933 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00023933 about?
NCT00023933 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer". Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells...
What is the current status of trial NCT00023933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2001-10.
What conditions does trial NCT00023933 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Adenocarcinoma of the Colon, Stage IV Colon Cancer.
What interventions are being tested in trial NCT00023933?
The interventions under investigation include: iodine I 131 monoclonal antibody CC49-deltaCH2 (DRUG).
Who is sponsoring clinical trial NCT00023933?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00023933 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Rectum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00023933's enrollment target sits among peer trials
15 12th of 11 the lowest of 11 other Adenocarcinoma of the Rectum trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Rectum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
COMPLETED · Phase 1
-
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia